Methyl 5-bromo-1-(2,6-dichlorophenyl)-2-oxo-3,4-dihydroquinazoline-7-carboxylate | 444663-85-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Methyl 5-bromo-1-(2,6-dichlorophenyl)-2-oxo-3,4-dihydroquinazoline-7-carboxylate
• CAS: 444663-85-8
• 化学式: C₁₆H₁₁BrCl₂N₂O₃
• 分子量: 430.085
• InChiKey: VUVUYDXSWJUTMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,6-二氟苯硼酸 、 Methyl 5-bromo-1-(2,6-dichlorophenyl)-2-oxo-3,4-dihydroquinazoline-7-carboxylate 在 四(三苯基膦)钯 作用下， 生成 Methyl 1-(2,6-dichlorophenyl)-5-(2,6-difluorophenyl)-2-oxo-1,2,3,4-tetrahydroquinazoline-7-carboxylate
  参考文献：
  名称：

  Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase

  摘要：

  The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38alpha MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38alpha inhibitor reported by Merck Research Laboratories and VX-745. Optimization of the C-5 phenyl and the C-7 piperidinyl substituents led to the identification of 15i which gave excellent suppression of TNF-alpha production in LPS-stimulated whole blood (IC50 = 10 nM) and good oral exposure in rats (F = 68%, AUCn PO = 0.58 muM h). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00752-7
• 作为产物：
  描述：

  methyl 5-bromo-1-(2,6-dichlorophenyl)-3-(4-methoxybenzyl)-2-oxo-1,2,3,4-tetrahydroquinazoline-7-carboxylate 在 三氟乙酸 作用下， 生成 Methyl 5-bromo-1-(2,6-dichlorophenyl)-2-oxo-3,4-dihydroquinazoline-7-carboxylate
  参考文献：
  名称：

  Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase

  摘要：

  The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38alpha MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38alpha inhibitor reported by Merck Research Laboratories and VX-745. Optimization of the C-5 phenyl and the C-7 piperidinyl substituents led to the identification of 15i which gave excellent suppression of TNF-alpha production in LPS-stimulated whole blood (IC50 = 10 nM) and good oral exposure in rats (F = 68%, AUCn PO = 0.58 muM h). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00752-7

文献信息

• Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase
  作者：John E. Stelmach、Luping Liu、Sangita B. Patel、James V. Pivnichny、Giovanna Scapin、Suresh Singh、Cornelis E.C.A. Hop、Zhen Wang、John R. Strauss、Patricia M. Cameron、Elizabeth A. Nichols、Stephen J. O'Keefe、Edward A. O'Neill、Dennis M. Schmatz、Cheryl D. Schwartz、Chris M. Thompson、Dennis M. Zaller、James B. Doherty

  DOI：10.1016/s0960-894x(02)00752-7

  日期：2003.1

  The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38alpha MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38alpha inhibitor reported by Merck Research Laboratories and VX-745. Optimization of the C-5 phenyl and the C-7 piperidinyl substituents led to the identification of 15i which gave excellent suppression of TNF-alpha production in LPS-stimulated whole blood (IC50 = 10 nM) and good oral exposure in rats (F = 68%, AUCn PO = 0.58 muM h). (C) 2002 Elsevier Science Ltd. All rights reserved.